IMMU-04. Multi-antigen T cell Infusion Against Neuro-oncologic Disease (ReMIND): A phase I clinical trial

Le résumé fourni par la source

Abstract Central nervous system (CNS) tumors are the most common, and deadliest, solid cancers in children, and novel therapies are urgently needed. We hypothesize that polyclonal multi-tumor-associated-antigen T-cell therapy (TAA-T) may benefit patients with high-risk brain tumors where intratumoral heterogeneity plays a prominent role in therapeutic resistance. Pediatric patients with high-risk CNS tumors were enrolled on a phase I dose escalation study (NCT03652545) to determine the safety and feasibility of autologous TAA-T expanded ex vivo using dendritic cells pulsed with peptide libraries spanning the antigens WT1, PRAME, and Survivin. Patients were enrolled at three dose levels in three strata: newly-diagnosed diffuse intrinsic pontine glioma (DIPG, Arm A, n = 11) and recurrent/progressive non-brainstem CNS malignancies without (Arm B, n = 18) or with (Arm C, n = 4) lymphodepletive conditioning (dose level 3 only). Arms B/C included high-grade glioma (n = 16), medulloblastoma (n = 9), ependymoma (n = 7), astroblastoma (n = 1), and pineoblastoma (n = 1). Infusions were generally well tolerated; however, two patients with high tumor burden experienced possibly-related serious adverse events (grade 5 for Arm A; grade 3 for Arm B). Dose level 3 (8x107 cells/m2) was established as the maximum tolerated dose. In Arm A, median overall survival was 12.9 months. In Arm B, one patient with glioblastoma exhibited prolonged post-­infusion survival of five years, two patients (medulloblastoma and glioblastoma) show no evidence of disease more than two years after TAA-T treatment, and one patient with medulloblastoma continues to exhibit prolonged disease stability more than three years post-infusion. In Arm C, one patient with H3K27M-­altered and TP53-altered spinal high-grade glioma, lived 27.3 months post-­infusion, and one patient with astroblastoma achieved a radiographic complete response and remains alive more than two years post-infusion without recurrence. TAA-T cells show some preliminary signals of efficacy and warrant further evaluation in patients with high-risk, non-brainstem CNS malignancies following tumor resection and adjuvant therapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.